Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2005 February;96(1) > Minerva Medica 2005 February;96(1):11-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

REVIEWS   

Minerva Medica 2005 February;96(1):11-8

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English, Italian

Brain natriuretic peptide and acute coronary syndrome

Mazzone M., Forte P., Portale G., Mancini F., Ursella S., La Sala M., Testa A., Covino M., Pignataro G., Gentiloni Silveri N.


PDF


The natriuretic peptide system (atrial natriuretic peptide, brain natriuretic peptide, BNP, and C natriuretic peptide) is an important marker of cardiac failure. These peptides are synthesized in atrial or ventricular myocytes in response to wall tension. In several studies the correlation between high BNP levels and mortality, in patients with acute coronary syndrome and heart failure, has been demonstrated. On the other hand, plasma levels of BNP could be considered as independent predictors of mortality in patients with heart failure. BNP could be used, for instance, as an early diagnostic marker for the differential diagnosis between cardiogenic and non cardiogenic dyspnea. In the Emergency Department its use will be important in the diagnosis of thoracic pain origin since it may help in the diagnostic and therapeutic course of this patient and to define the modality of hospitalization. Moreover, it can be used as a marker of heart failure severity and as an important negative prognostic factor. Some studies have confirmed that plasma BNP reflects the degree of left ventricular dysfunction and the prognostic significance after acute myocardial infarction and chronic heart failure.

top of page